North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-06-02 Denosumab
| Denosumab Stoboclo® (biosimilar) |
|
Formulary
|
Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who don't tolerate bisphosphonates or strontium ranelate. Supporting information on use of denosumab biosimilars: |
 NICE TA204: Osteoporotic fractures - denosumab MHRA Drug Safety Updates: Denosumab NENC Shared Care Protocol - Denosumab for primary and secondary prevention of fracture in women and men over the age of 50 |
|
| Denosumab Xgeva® |
|
Formulary
|
|
|
MHRA Drug Safety Updates: Denosumab NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
|
Links
- MHRA Drug Safety Update (Dec 2014): Bisphosphonates: atypical femoral fractures
- MHRA Drug Safety Update (Dec 2014): Bisphosphonates: osteonecrosis of the jaw
- MHRA Drug Safety Update (Dec 2014: Bisphosphonates: atrial fibrillation
- MHRA Drug Safety Update (Dec 2015): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA Drug Safety Updates: Denosumab
- MHRA Drug Safety Updates: Denosumab
- MHRA Drug Safety Updates: Denosumab
- NENC Shared Care Protocol - Denosumab for primary and secondary prevention of fracture in women and men over the age of 50
- NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA204: Osteoporotic fractures - denosumab
- NICE TA265: Bone metastases from solid tumours - denosumab: guidance
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA791: Romosozumab for treating severe osteoporosis
- NICE TA993 : Burosumab for treating X-linked hypophosphataemia in adults
- North East and North Cumbria Integrated Care System Guideline for the management of osteoporosis in primary care
- NTAG Endocrine System Recommendations